38,848 results match your criteria hcc patients


Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion.

J Cancer Res Clin Oncol 2021 Jun 12. Epub 2021 Jun 12.

Division of Radiology, Shifa International Hospital Islamabad, Islamabad, Pakistan.

Background: The indications for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) continue to evolve. The aim of this study was to report outcomes in patients who underwent living donor liver transplantation (LDLT) for HCC outside traditional criteria including macrovascular invasion (MVI).

Methods: We reviewed outcomes in patients who met the University of California San Francisco (UCSF) criteria (n = 159) and our center-specific criteria (UCSF+) (largest tumor diameter ≤ 10 cm, any tumor number, AFP ≤ 1000 ng/ml) (n = 58). Read More

View Article and Full-Text PDF

Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma.

Eur Radiol 2021 Jun 12. Epub 2021 Jun 12.

Department of Medical and Surgical Sciences - DIMEC, Alma Mater Studiorum - University of Bologna, Bologna, Italy.

Objectives: To evaluate the inter-observer reliability of modified Response Evaluation Criteria In Solid Tumours (mRECIST) of patients with hepatocellular carcinoma (HCC) undergoing neo-adjuvant treatments before liver transplant (LT). The agreement of tumor number, size, transplant criteria, and the radiological-pathological concordance were also assessed.

Methods: A total of 180 radiological studies before/after neo-adjuvant therapies performed on 90 patients prior to LT were reviewed from three expert centers. Read More

View Article and Full-Text PDF

Integrated I-125 Seed Implantation Combined with Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombus.

Cardiovasc Intervent Radiol 2021 Jun 11. Epub 2021 Jun 11.

Department of Interventional Radiology, First Affiliated Hospital, Soochow University, No. 188 Shizi Road, Suzhou, 215006, China.

Purpose: To compare the safety and efficacy of integrated iodine-125 (I-125) seed implantation (sequential implantation of helical I-125 seed implant into the main portal vein and of I-125 seeds into the branch tumor thrombus directly forming main portal vein tumor thrombus (MPVTT)) combined with transarterial chemoembolization (TACE) versus TACE alone for hepatocellular carcinoma (HCC) with MPVTT.

Materials And Methods: From December 2016 to January 2020, 46 HCC patients with MPVTT were analyzed. In the combination group, 21 patients received helical I-125 seed implantation in the main portal vein through a patent small portal vein branch and TACE in a single session. Read More

View Article and Full-Text PDF

Hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein thrombosis: a case-control study.

Clin Radiol 2021 Jun 8. Epub 2021 Jun 8.

Endemic Medicine and Hepatogastroenterology Department, Cairo University, Cairo, Egypt.

Aim: To study the treatment efficacy and survival of hepatic arterial infusion chemotherapy (HAIC) for patients with advanced hepatocellular carcinoma (HCC) and portal vein tumour thrombosis (PVTT) with compensated cirrhosis in comparison with sorafenib as the standard of care therapy versus best supportive care (BSC).

Materials And Methods: This case-control study included 91 patients with advanced HCC and PVTT divided into three groups: Group 1 20 treated with HAIC, (50 mg adriamycin and 50 mg cisplatin were infused in hepatic artery); Group 2, 42 patients treated with BSC; and Group 3, 29 patients treated with sorafenib. Patients were followed up for assessment and comparison of treatment outcome by modified Response Evaluation Criteria in Solid Tumours (mRECIST) and survival. Read More

View Article and Full-Text PDF

Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma.

BMC Cancer 2021 Jun 11;21(1):693. Epub 2021 Jun 11.

Department of Interventional Radiology, The Second Clinical College of North Sichuan Medical College, Nan Chong Central Hospital, Nan Chong, 637000, Sichuan, China.

Backgrounds: Liver hepatocellular carcinoma (HCC) is one of the most malignant tumors, of which prognosis is unsatisfactory in most cases and metastatic of HCC often results in poor prognosis. In this study, we aimed to construct a metastasis- related mRNAs prognostic model to increase the accuracy of prediction of HCC prognosis.

Methods: Three hundred seventy-four HCC samples and 50 normal samples were downloaded from The Cancer Genome Atlas (TCGA) database, involving transcriptomic and clinical data. Read More

View Article and Full-Text PDF

Severe steatosis and mild colitis are important for the early occurrence of hepatocellular carcinoma.

Biochem Biophys Res Commun 2021 Jun 8;566:36-44. Epub 2021 Jun 8.

Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757, Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan. Electronic address:

The number of patients with non-alcoholic steatohepatitis (NASH) and inflammatory bowel disease (IBD) is increasing. This study elucidates the effect of both NASH and IBD on hepatocellular carcinoma (HCC) using a mouse model combining NASH and IBD. The melanocortin 4 receptor-deficient (Mc4r-KO) mice were divided into four groups with or without a high-fat diet (HFD) and with or without dextran sulfate sodium (DSS) to induce colitis, and the differences in liver damage and occurrence of HCC were analyzed. Read More

View Article and Full-Text PDF

Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.

Bioengineered 2021 Dec;12(1):2664-2675

Department of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu, P.R. China.

Rad51, a DNA-repair-related gene, has been reported to be involved in multiple cancers. However, its link with immune infiltration in liver cancer still unknown. Therefore, more research into the roles and activities of Rad51 in hepatocellular carcinoma (HCC) is required. Read More

View Article and Full-Text PDF
December 2021

No Foul Play for Transjugular Intrahepatic Portosystemic Shunts in Liver Transplant for Hepatocellular Carcinoma.

Liver Transpl 2021 Jun 11. Epub 2021 Jun 11.

Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Transjugular intrahepatic portosystemic shunt (TIPS) can be placed to treat or prevent complications of portal hypertension in patients with cirrhosis, yet little is known about the effects of TIPS placement on diagnosis or liver transplant (LT) outcomes in patients with hepatocellular carcinoma (HCC). We read with interest the recent retrospective analysis from Krumeich et al. suggesting that the presence of TIPS may alter radiographic HCC visualization, leading to under-staging and underdiagnosis of HCC - or occult disease - prior to LT (1). Read More

View Article and Full-Text PDF

Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study.

Qual Life Res 2021 Jun 11. Epub 2021 Jun 11.

AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA.

Purpose: This study aimed to elucidate the patient experience of hepatocellular carcinoma (HCC) to guide patient-centered outcome measurement in drug development.

Methods: Patients with HCC participated in qualitative interviews to elicit disease-related signs/symptoms and impacts, using discussion guides developed from literature searches and discussions with oncologists. Interview participants rated the disturbance of their experiences (0-10 scale). Read More

View Article and Full-Text PDF

Liver stiffness measured by magnetic resonance elastography in early recurrence of hepatocellular carcinoma after treatment: A protocol for systematic review and meta analysis.

Medicine (Baltimore) 2021 Jun;100(23):e26183

Department of Radiological, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei Province, China.

Background: With high diagnostic accuracy, magnetic resonance elastography (MRE) is a noninvasive tool and can be adopted to measure liver stiffness (LS). In this study, meta-analysis was carried out to further evaluate whether LS measured by MRE can predict early recurrence in patients with hepatocellular carcinoma (HCC).

Methods: PUBMED, EMBASE, Web of Science, China National Knowledge Infrastructure, and Cochrane Library database were searched for studies related to LS measured by MRE in the prediction of recurrence in patients with HCC. Read More

View Article and Full-Text PDF

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.

Cancer Rep (Hoboken) 2021 Jun 11:e1464. Epub 2021 Jun 11.

Department of Internal Medicine, Himeji Red Cross Hospital, Hyogo, Japan.

Background: Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u-HCC), changes in hepatic function during therapy have yet to be reported.

Aim: This retrospective clinical study aimed to elucidate early responses to Atez/Bev.

Methods: From September 2020 to April 2021, 171 u-HCC patients undergoing Atez/Bev treatment were enrolled (BCLC stage A:B:C:D = 5:68:96:2). Read More

View Article and Full-Text PDF

Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.

Hepatology 2021 Jun 11. Epub 2021 Jun 11.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Background & Aims: Intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) are the most common primary liver cancers. Differences in their clinical features and outcomes have not been investigated in a large-scale study. We aim to investigate the differences in clinical features and outcomes between iCCA and HCC. Read More

View Article and Full-Text PDF

USP11 degrades KLF4 via its deubiquitinase activity in liver diseases.

J Cell Mol Med 2021 Jun 10. Epub 2021 Jun 10.

Department of Predictive Toxicology, Korea Institute of Toxicology, Daejeon, Korea.

Krüppel-like factor 4 (KLF4) is a zinc-finger containing DNA-binding transcription factor involved in tumorigenesis and acts as a tumour suppressor or an oncogene depending on the tissue. In hepatocellular carcinoma (HCC), KLF4 has been considered as a tumour suppressor, although the mechanism underlying its action remains largely unknown. In this study, we identified the ubiquitin-specific peptidase USP11 as a KLF4-interacting deubiquitinating enzyme using a proteomic approach. Read More

View Article and Full-Text PDF

Role of LncRNAs in the Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.

Front Oncol 2021 25;11:690800. Epub 2021 May 25.

Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Hepatocellular carcinoma (HCC) is a type of primary liver cancer with a high incidence and mortality rate. HCC develops insidiously, and most newly diagnosed cases are in the middle and advanced stages. The epithelial-mesenchymal transition (EMT) is a vital mechanism underlying metastasis in patients with advanced HCC. Read More

View Article and Full-Text PDF

Establishment and Evaluation of a Predictive Model for Early Postoperative Recurrence of Hepatocellular Carcinoma in Patients with Microvascular Invasion.

Int J Gen Med 2021 3;14:2259-2274. Epub 2021 Jun 3.

Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, 100021, People's Republic of China.

Objective: The present study aimed to identify the risk factors for early postoperative recurrence of hepatocellular carcinoma (HCC) in patients with microvascular invasion (MVI) and develop a predictive model.

Inclusion Population And Methods: Patients who underwent surgery for HCC with pathological identification of MVI at the Cancer Hospital of the Chinese Academy of Medical Sciences from January 2014 to June 2019 were consecutively enrolled in this study. A total of 416 patients were included, divided into an early recurrence group (N = 169) and a non-early recurrence group (N = 247), taking 12 months as the cut-off point for early recurrence. Read More

View Article and Full-Text PDF

The short-term safety and efficacy of TANDEM microspheres of various sizes and doxorubicin loading concentrations for hepatocellular carcinoma treatment.

Sci Rep 2021 Jun 10;11(1):12277. Epub 2021 Jun 10.

Department of Radiology, Chang-Hua Christian Hospital, No. 135, Nan-Xiao Street, Changh-Hua City, Changhua County, 500, Taiwan, ROC.

Drug-eluting bead transarterial chemoembolization (DEB-TACE) is the most common treatment for unresectable hepatocellular carcinoma (HCC). However, the effect of drug loading concentration and microsphere size on treatment outcomes remains unclear. This retrospective study compares the outcomes of 87 HCC patients who underwent DEB-TACE with half-loaded or full-loaded doxorubicin (maximum capacity 50 mg/mL) in 75-µm or 100-µm microspheres. Read More

View Article and Full-Text PDF

Blocking siglec-10 tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma.

Exp Hematol Oncol 2021 Jun 10;10(1):36. Epub 2021 Jun 10.

Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

Background: Tumor-associated macrophages (TAMs) promote key processes in the modulation of tumor microenvironment (TME). However, the clinical significance of heterogeneous subpopulations of TAMs in hepatocellular carcinoma (HCC) remains unknown.

Methods: HCC tissues from Zhongshan Hospital and data from The Cancer Genome Atlas were obtained and analyzed. Read More

View Article and Full-Text PDF

A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.

World J Surg Oncol 2021 Jun 10;19(1):168. Epub 2021 Jun 10.

Department of Oncology, The Second Affiliated Hospital of Nanchang University, No. 1, Minde Road, Nanchang, 330006, Jiangxi Province, People's Republic of China.

Background: Sorafenib was reported as a useful adjuvant treatment in patients with hepatocellular carcinoma who underwent surgical resection. However, its therapeutic value remains controversial. This meta-analysis examined the available data regarding the efficacy and safety of sorafenib in patients with hepatocellular carcinoma after radical surgery. Read More

View Article and Full-Text PDF

A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.

BMC Cancer 2021 Jun 10;21(1):686. Epub 2021 Jun 10.

Organ Transplantation Center, the First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, 650032, Yunnan Province, China.

Background: Hepatitis B Virus (HBV) contributes to liver carcinogenesis via various epigenetic mechanisms. The newly defined epigenetics, epitranscriptomics regulation, has been reported to involve in multiple cancers including Hepatocellular Carcinoma (HCC). Our previous study found that HBx, HBV encodes X protein, mediated H3K4me3 modification in WDR5-dependent manner to involve in HBV infection and contribute to oncogene expression. Read More

View Article and Full-Text PDF

Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.

BMC Cancer 2021 Jun 10;21(1):687. Epub 2021 Jun 10.

Department of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.

Background: The baculoviral IAP repeat containing 5 (BIRC5) related to epithelial-mesenchymal transition (EMT) plays a crucial role in the pathogenesis of hepatocellular carcinoma (HCC). However, it remains unclear whether BIRC5-related genes can be used as prognostic markers of HCC.

Methods: Kaplan-Meier (K-M) survival curve was used to assess the Overall Survival (OS) of high- and low-expression group divided by the median of BIRC5 expression. Read More

View Article and Full-Text PDF

Osteoclast-like giant cells in hepatocellular carcinoma Case description and review of the literature.

Acta Chir Belg 2021 Jun 10:1-20. Epub 2021 Jun 10.

Department of Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.

The presence of osteoclast-like giant cells in hepatocellular carcinoma (HCC) is rare and literature on this topic is scarce. In this article we report on a case of a 77-year-old male patient with HCC with osteoclast-like giant cells and provide an overview of the current literature. We conducted a systematic search to find all available literature on osteoclast-like giant cells in HCC. Read More

View Article and Full-Text PDF

Identifying Dendritic Cell-Related Genes Through a Co-Expression Network to Construct a 12-Gene Risk-Scoring Model for Predicting Hepatocellular Carcinoma Prognosis.

Front Mol Biosci 2021 24;8:636991. Epub 2021 May 24.

Department of Gastroenterology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.

The prognostic prediction of hepatocellular carcinoma (HCC) is still challenging. Immune cells play a crucial role in tumor initiation, progression, and drug resistance. However, prognostic value of immune-related genes in HCC remains to be further clarified. Read More

View Article and Full-Text PDF

SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells.

Cell Death Dis 2021 Jun 2;12(6):570. Epub 2021 Jun 2.

Department of Gastroenterology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China.

The main reason for poor prognosis in hepatocellular carcinoma (HCC) patients is high metastasis and recurrence. Cancer progression depends on a tumor-supportive microenvironment. Therefore, illustrating the mechanisms of tumor immunity in underlying HCC metastasis is essential. Read More

View Article and Full-Text PDF

[Effectiveness of TRB3 on human hepatocellular carcinoma cells proliferation, apoptosis and migration].

Zhonghua Gan Zang Bing Za Zhi 2021 May;29(5):439-445

Department of Hepatobiliary Surgery, Affiliated Min da Hospital of Hubei Institute for Nationalities, Enshi 445000, China.

To explore the regulatory role and mechanism of tribbles pseudokinase 3 (TRB3) on hepatocarcinoma (HCC) cells proliferation, apoptosis and migration. Immunohistochemistry and Western blot were used to detect TRB3 expression in cancerous and adjacent cancerous liver tissues of HCC patients. TRB3 expression was detected in vitro in HepG2 and Huh7 hepatocarcinoma cell lines. Read More

View Article and Full-Text PDF

Magnetic resonance radiomics signatures for predicting poorly differentiated hepatocellular carcinoma: A SQUIRE-compliant study.

Medicine (Baltimore) 2021 May;100(19):e25838

Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Abstract: Radiomics contributes to the extraction of undetectable features with the naked eye from high-throughput quantitative images. In this study, 2 predictive models were constructed, which allowed recognition of poorly differentiated hepatocellular carcinoma (HCC). In addition, the effectiveness of the as-constructed signature was investigated in HCC patients. Read More

View Article and Full-Text PDF

Atrial reconstruction, distal gastrectomy with Ante-situm liver resection and autotransplantation for hepatocellular carcinoma with atrial tumor thrombus: A case report.

Medicine (Baltimore) 2021 May;100(19):e25780

Department of Liver Transplantation & Laparoscopic Surgery, Center of Organ Transplantation, The 1st Affiliated Hospital of Xinjiang Medical University.

Rationale: Hepatocellular with tumor thrombi extending into 3 hepatic veins (HVs) and right atrium presents as a real clinical challenge. We report the first documented case of surgical resection of an advanced hepatocellular carcinoma (HCC) with extensive invasion to distal stomach, atrium and hepatic vasculatures.

Patient Concerns: We present a case of 48-years old man with abdominal mass accompanying shortness of breath after activities. Read More

View Article and Full-Text PDF

Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound.

Cancer Rep (Hoboken) 2021 Jun 9:e1471. Epub 2021 Jun 9.

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.

Background: The antitumor effect of a drug is considered to be associated with a decrease in tumor blood flow.

Aims: We investigated whether the efficacy of lenvatinib (LEN) could be accurately assessed by measuring blood flow in hepatocellular carcinoma (HCC) during early treatment stages.

Methods And Results: Blood flow changes and treatment results of 19 patients who underwent contrast-enhanced ultrasound (CEUS), before and after LEN administration, in Kurume University Hospital from July 2018 to June 2020 were examined. Read More

View Article and Full-Text PDF

Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.

J Viral Hepat 2021 Jun 9. Epub 2021 Jun 9.

Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Science, Hiroshima, Japan.

While the preS1 region of the large hepatitis B surface protein plays an essential role in hepatitis B virus (HBV) infection, the effect of preS1 on liver fibrosis and hepatocarcinogenesis in chronic hepatitis B (CHB) patients is not well known. In this study, we measured serum preS1 levels by chemiluminescent immunoassay technology in 690 CHB patients and evaluated the correlation between serum preS1 levels and HBV, liver function markers and liver inflammation, fibrosis assessed by histological findings. Predictive factors for hepatocellular carcinoma (HCC) development in patients who had no previous history of HCC at the time of preS1 level measurement were also analyzed. Read More

View Article and Full-Text PDF

Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma.

J Hepatocell Carcinoma 2021 31;8:513-527. Epub 2021 May 31.

Liver Imaging Group, Department of Radiology, University of California San Diego, La Jolla, CA, USA.

Hepatocellular carcinoma (HCC) is a leading cause of mortality worldwide and a major healthcare burden in most societies. Computed tomography (CT) and magnetic resonance imaging (MRI) play a pivotal role in the medical care of patients with or at risk for hepatocellular carcinoma (HCC). When stringent imaging criteria are fulfilled, CT and MRI allow for diagnosis, staging, and assessment of response to treatment, without the need for invasive workup, and can inform clinical decision making. Read More

View Article and Full-Text PDF

Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma.

J Hepatocell Carcinoma 2021 31;8:507-512. Epub 2021 May 31.

Gastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Introduction: Patients with advanced hepatocellular carcinoma have a dismal prognosis; only a subset of patients with advanced HCC will benefit from treatment with immunotherapy. We searched for clinical characteristics predicting exceptional long-term survival in HCC patients treated with immune checkpoint inhibitors.

Methods: We compared clinical characteristics of 59 patients with advanced hepatocellular carcinoma treated with immunotherapy with and without locoregional therapy between 2013-2019. Read More

View Article and Full-Text PDF